XCR Xcorporeal, Inc.

Xcorporeal, Inc. (AMEX:XCR) announced today�that renowned business columnist Gene Marcial of BusinessWeek Magazine highlighted Xcorporeal in the most recent edition of the magazine dated March 24, 2008. The article is also available online at http://www.businessweek.com/magazine/content/08_12/c4076insidewal 342033.htm?chan=magazine+channel_opinion. (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.) According to the article, Xcorporeal, which has developed a battery-powered, wearable dialysis machine, is catching the eye of some investors. �The new, smaller version could be more effective than conventional types that require daily or thrice-weekly treatments in hospitals," says Marc Cummins, a company Director and fund manager of Prime Capital, which has acquired 6.7%, or 1 million shares. Xcorporeal also makes portable machines for home or hospital use. "The portables will have great impact on patients suffering from kidney failure," says Cummins. He expects the stock to soar once the Food & Drug Administration OKs the portables for home use, expected in late 2009. Jay Wolf, a company director and fund manager of Trinad Capital, with a 2.5% stake, says the machines are less costly, and more efficient. About Xcorporeal Xcorporeal, Inc. is a medical device company developing an innovative extra-corporeal platform technology that may be used in devices to replace the function of various human organs. The platform will lead to three initial products; the first, a device for hospital Renal Replacement Therapy (RRT), another device for home hemodialysis and the Wearable Artificial Kidney (WAK) for continuous ambulatory hemodialysis. These devices will seek to provide patients with improved, efficient and cost effective therapy. The RRT markets represent multibillion dollar opportunities. For the RRT market, Xcorporeal is developing a portable, multifunctional renal replacement device that will offer cost effective therapy for those patients suffering from Acute Renal Failure (ARF) which causes a rapid decline in kidney function. In the U.S., the disease affects more than 200,000 patients annually, with a mortality rate of 50%. The Xcorporeal platform technology is a natural fit for the hospital market of renal replacement therapy since the technology is designed to provide cost-effective, continuous therapy. The projected 2008 market opportunity for the U.S. is approximately $1.1 billion. The disposable market is expected to grow at 10% per year. Hospital-based devices typically need to be replaced every five years. The Company has completed its functional prototype of the product, which is currently undergoing bench testing, and intends to generate an initial filing with the Food and Drug Administration (FDA), under a 510(k), during the fourth quarter of 2008. Xcorporeal also plans to commercialize a home hemodialysis machine for the End Stage Renal Disease (ESRD) market, which are patients in which the kidneys cease to function. Xcorporeal's devices will combine the best attributes of currently marketed home hemodialysis machines to create hemodialysis devices which offer patients convenient, durable and truly portable devices for home use. The Company believes its machines will provide a cost-effective alternative to current home treatment modalities, due to their ability to offer hemodialysis without the need for large quantities of dialysate fluid or purified water. The Company has completed its functional prototype of the product, which is currently undergoing bench testing, and intends to generate an initial filing with the FDA, under a 510(k), during the second half of 2009. The WAK will be a revolutionary device intended to enable patients with ESRD to achieve a quality of life closer to that of healthy individuals. The WAK has recently been featured in articles written by The Los Angeles Times, The Lancet, Kidney International and various other medical periodicals. Additional Company information may be found on the Internet at: www.xcorporeal.com. Forward-Looking Statements Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and substantial regulation in the medical device industry; and additional risks factors as discussed in the reports filed by the company with the Securities and Exchange Commission, which are available on its website at http://www.sec.gov.